We can not find a paper reporting a clinical trial in which crst3123 was used. We must therefore question the validity of the claimed efficacy of the investigational product.
CRS3123 has a well defined mechanism of action against C. acnes biofilm associated with acne. This activity appears to be a result of a disruption of the balance between the two major pathways of C. acnes, commensal and pathogenic.
Crs3123 inhibits key steps of the intracellular pathways of Mycobacterium tuberculosis and Mycobacterium leprae, the causative agents of the deadly diseases leprosy and lepromatous leprosy respectively.\n
Most bacterial infections are asymptomatic, and the onset of symptoms is very nonspecific, so many cases can be attributed to viral infection at first presentation. Other symptoms include sore throat, pharyngitis, tonsilitis and cellulitis. Severe septic manifestations are often difficult to diagnose even by modern microbiology. If bacterial infections are suspected, then it is important to evaluate the patient for symptoms of an underlying metabolic disorder which may include sepsis, hyperthermia or low blood sugar. Once these manifestations are apparent, cultures should usually be obtained. Finally, specific antibiotic therapy can be initiated. When antibiotic therapy is initiated, it is most appropriate to start the antibiotic based on local data of the common bacterial causes.
In people with Crohn's ileitis who are treated with surgery and standard antimicrobial regimens, clostridium infections are rare. Nevertheless, Crohn's recipients should be cautioned that they often do not have a complete eradication of clostridium species from the colon, even after the initiation of antimetacidal therapy.
This article discusses the current evidence that clostridia have an important role in many diseases from an immunological to metabolic or neurotoxic way. It also shows that clostridium infections can occur in many diseases. In addition to a more detailed characterization the role of other microbe and the effect of microbes on host cells are discussed.
There are many different therapeutic options that are given to people to treat the symptoms of clostridum infection. When faced with an unexpected CABE, the first step is to identify the organism, because if the causative organism is unknown, treatment will be difficult. It is important to keep in mind the fact that a CABE can be a self-resolving process, and as soon as the infection is recognized and treatment begun, it may resolve in a short time.
It is estimated that there will be around 12 million invasive C. difficile colonization cases and more than 700,000 cases of C. difficile-associated disease each year in the USA, resulting in up to 28,600 deaths. It is estimated that at least 80,000 people with C. difficile will die each year.
Clostridium histolyticum is a bacterial pathogen that affects all age groups, especially children, and can cause intestinal perforations and gas gangrene. Clinically speaking, it can have many symptoms resembling those of appendicitis or diverticulitis, but its most frequent clinical presentation is the one of hemorrhagic sepsis with abscess formation, which can usually only be detected by use of a computed tomography scan. Clostridial toxins can cause necrosis, inflammation of blood vessels, and arterial thrombosis, leading to ischemic heart diseases and stroke in addition to death.
The most common side effects in the 495 patients were [nausea (2.5%), headache (2.1%), diarrhea (2.1%), upper respiratory tract infection (2.0%), dysuria (2%), constipation (1.8%), fever (1.2%), pharyngitis (1.1%), vomiting (1%), dyspnea (1%)], and muscle pain (1%). All were considered to be mild in severity. One (0.1%) patient (male, 52 y/o) died in the study. (http://www.clinicaltrials.gov/ NCT00074624).
A novel agent, CRS3123 is a novel agent that possesses antibacterial properties against gram-positive and gram-negative species and is specifically active against "Mycoplasma suis", as well as other Mycoplasma species. There were no observed toxicities for the compound or for its dosing regimes evaluated in this study. Furthermore, it has shown therapeutic efficacy in reducing the number of "Helicobacter canis" inoculants in stool of infected subjects, suggesting that CRS3123 has the potential to be utilized as an antimicrobial agent for the treatment of infections in humans.
CCR5-543 had a significantly increased chance of infection resolution compared with placebo. We suspect that the increased CR5-543 uptake at the site of infection may reduce its effects of recruiting other leukocyte populations to sites of infection, thereby preventing an uncontrolled inflammatory response. CCR5-receptor inhibitors therefore may be of interest therapeutically.